Sarcosine and depression

What 2 graded rows on sarcosine agree on for depression, and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the Sarcosine page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the Sarcosine page, with its PubMed record.

Supplement

Sarcosine Choose another

2 rows · 100 people

They agree: both rows found an improvement.

No difference

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside.

From the rows

The best-graded row, grade D, is a randomized trial of 60 people (2024) and found an improvement.

The rows run from 40 to 60 people, published from 2013 to 2024: 2 single studies.

2 improved

Grade DDepression score (MADRS) when added to an SSRI · Improved
RCT · n 60 · 2024 · Adults with major depressive disorder on SSRIs
Not stated in the abstract · 8 weeks
MADRS fell by 13.3 points with sarcosine versus 8.7 with placebo (difference −4.6, 95% CI −7.5 to −1.7); response and remission rates were higher.
Row on the Sarcosine page · PubMed 39180989 (opens PubMed)
Grade DDepression scores versus citalopram · Improved
RCT · n 40 · 2013 · Adults with major depressive disorder
Not stated in the abstract · 6 weeks
Sarcosine improved Hamilton depression, clinical global impression and functioning scores more than citalopram, with faster remission and fewer dropouts; no significant side effects.
Row on the Sarcosine page · PubMed 23562005 (opens PubMed)